Efficacy and effects of reflimab: anti-cancer mechanism and therapeutic effect

Retifanlimab (Retifanlimab) is a new type of immunotherapy drug that is a programmed cell death protein 1 (PD-1) inhibitor. In recent years, immunotherapy has made major breakthroughs in the field of tumor treatment. Riflimab, as an immune checkpoint inhibitor, has shown significant anti-cancer potential, especially in the treatment of certain malignant tumors. Riflimab exerts its anti-cancer effect by dismantling the escape mechanism of cancer cells from the immune system, activating the body's immune response, and enhancing the ability of T cells to attack tumors.

The anti-cancer mechanism of Riflimab mainly targets PD-1 receptor intervention. PD-1 is a negative immune regulatory receptor that mainly exists on the surface of T cells. Under normal physiological conditions, when PD-1 binds to its ligand PD-L1, it inhibits the activity of T cells to prevent the immune system from inadvertently damaging normal cells. However, many tumor cells express PD-L1 and combine with PD-1 to inhibit the immune system's recognition and attack of cancer cells, allowing tumor cells to evade the body's immune surveillance.

Riflimab blocks the interaction between PD-1 and PD-L1 by binding toPD-1 receptor, thereby releasing the inhibition of T cells, restoring their immune function, and enhancing the attack power of T cells against tumor cells. This mechanism is not limited to inhibiting tumor cell proliferation, but can also enhance the body's autoimmune response and provide a more durable anti-tumor effect.

In clinical application, the therapeutic effect of reflimab has been verified in various types of malignant tumors. The main indications include Merkel cell carcinoma (MCC) and squamous cell carcinoma (SCAC). These tumors usually have strong immune evasion properties and traditional treatments have limited effectiveness. Riflimab, as an immune checkpoint inhibitor, can significantly enhance the anti-tumor ability of T cells, thereby improving the prognosis of patients.

In the treatment of Merkel cell carcinoma, riflimab has shown significant efficacy, especially for patients with metastatic or recurrent locally advanced disease. Its application can effectively delay tumor progression and improve survival rate. Compared with traditional chemotherapy, riflimab has fewer side effects and can achieve longer-lasting effects in some patients.

For squamous cell carcinoma, the effect of reflimab is also outstanding. When used in combination with drugs such as carboplatin and paclitaxel, reflimab becomes one of the first-line treatment options, especially for patients with inoperable locally recurrent or metastatic disease. For those patients whose disease has progressed after receiving platinum-based chemotherapy, reflimab monotherapy also shows positive effects, effectively delaying disease progression and improving progression-free survival (PFS).

Although the therapeutic effect of reflimab is remarkable, its side effects are also worthy of attention. The side effects of immune checkpoint inhibitors mainly originate from over-activation of the immune system. Common side effects include rash, fatigue, gastrointestinal discomfort, etc., which are usually mild or moderate and can be alleviated by adjusting the dose or symptomatic treatment. However, in some cases, severe immune-related inflammatory reactions may occur, such as hepatitis, pneumonia, etc. These side effects are relatively rare, but need to be managed in time. When patients receive refulimab treatment, they need to have regular physical examinations and maintain close communication with their doctors to ensure safe use.

In addition, riflimab can be used in combination with other immunotherapy drugs to further improve efficacy. By combining it with CTLA-4 inhibitors or targeted therapies, the anti-tumor effect of reflimab may be significantly enhanced.

Reference materials:https://www.drugs.com/mtm/retifanlimab.html